C
Clover Biopharmaceuticals Ltd
HKEX:2197
Clover Biopharmaceuticals Ltd
HKEX:2197
Price:
2.92
HKD
-5.81%
Market Closed
Market Cap:
HK$3.8B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Clover Biopharmaceuticals Ltd
HKEX:2197
|
CN |
|
G
|
Greatime International Holdings Ltd
HKEX:844
|
HK |
|
Garware Hi-Tech Films Ltd
BSE:500655
|
IN |
Income Statement
Earnings Waterfall
Clover Biopharmaceuticals Ltd
Clover Biopharmaceuticals Ltd
Income Statement
Clover Biopharmaceuticals Ltd
Clover Biopharmaceuticals Ltd
Currency: CNY
| Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||
| Interest Expense |
6
|
0
|
19
|
0
|
6
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
39
+15 174%
|
29
-26%
|
38
+33%
|
52
+35%
|
4
-93%
|
|
| Gross Profit | ||||||||
| Cost of Revenue |
0
|
(0)
|
(15)
|
(13)
|
(17)
|
(19)
|
(1)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
24
+43 975%
|
16
-35%
|
22
+36%
|
32
+50%
|
3
-92%
|
|
| Operating Income | ||||||||
| Operating Expenses |
(2 386)
|
(577)
|
(2 613)
|
(967)
|
(960)
|
(976)
|
(208)
|
|
| Selling, General & Administrative |
(444)
|
(317)
|
(264)
|
(180)
|
(95)
|
(80)
|
(71)
|
|
| Research & Development |
(1 465)
|
(996)
|
(650)
|
(363)
|
(183)
|
(168)
|
(182)
|
|
| Other Operating Expenses |
(476)
|
735
|
(1 699)
|
(424)
|
(682)
|
(728)
|
46
|
|
| Operating Income |
(2 386)
N/A
|
(577)
+76%
|
(2 589)
-348%
|
(951)
+63%
|
(938)
+1%
|
(944)
-1%
|
(205)
+78%
|
|
| Pre-Tax Income | ||||||||
| Interest Income Expense |
(23)
|
(83)
|
(38)
|
34
|
(6)
|
14
|
(0)
|
|
| Non-Reccuring Items |
(44)
|
(5)
|
2 488
|
33
|
40
|
20
|
(0)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(2 452)
N/A
|
(665)
+73%
|
(139)
+79%
|
(884)
-538%
|
(903)
-2%
|
(910)
-1%
|
(205)
+77%
|
|
| Net Income | ||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(2 452)
|
(665)
|
(139)
|
(884)
|
(903)
|
(910)
|
(205)
|
|
| Net Income (Common) |
(2 452)
N/A
|
(665)
+73%
|
(139)
+79%
|
(884)
-538%
|
(903)
-2%
|
(910)
-1%
|
(205)
+77%
|
|
| EPS (Diluted) |
-2.22
N/A
|
-0.53
+76%
|
-0.11
+79%
|
-0.71
-545%
|
-0.72
-1%
|
-0.72
N/A
|
-0.16
+78%
|
|
Switch to:
Switch to:
See Also
Discover More
